Insulet Corporation $PODD Stake Lessened by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd reduced its position in Insulet Corporation (NASDAQ:PODD) by 70.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,319 shares of the medical instruments supplier’s stock after selling 36,565 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Insulet were worth $3,187,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Angeles Wealth Management LLC lifted its stake in Insulet by 5.3% in the first quarter. Angeles Wealth Management LLC now owns 2,725 shares of the medical instruments supplier’s stock valued at $572,000 after buying an additional 136 shares during the last quarter. C WorldWide Group Holding A S raised its holdings in shares of Insulet by 17.7% in the 1st quarter. C WorldWide Group Holding A S now owns 99,908 shares of the medical instruments supplier’s stock worth $20,965,000 after purchasing an additional 15,000 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. grew its holdings in shares of Insulet by 38.9% in the 1st quarter. Financiere des Professionnels Fonds d investissement inc. now owns 2,398 shares of the medical instruments supplier’s stock worth $503,000 after acquiring an additional 671 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Insulet by 12.3% in the 1st quarter. Bessemer Group Inc. now owns 4,024 shares of the medical instruments supplier’s stock valued at $845,000 after acquiring an additional 442 shares in the last quarter. Finally, Aware Super Pty Ltd as trustee of Aware Super purchased a new position in shares of Insulet during the first quarter valued at $3,386,000.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Robert W. Baird cut their target price on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. UBS Group set a $219.00 price objective on shares of Insulet in a report on Thursday, June 11th. Leerink Partners lowered their target price on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Insulet in a report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price objective on the stock. Finally, Wells Fargo & Company lowered their price objective on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $235.25.

Insulet Stock Up 2.0%

Shares of NASDAQ PODD opened at $167.37 on Tuesday. The firm’s 50-day moving average is $153.27 and its 200-day moving average is $205.49. The firm has a market capitalization of $11.59 billion, a PE ratio of 38.92, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period last year, the company posted $1.02 EPS. Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.45 EPS for the current year.

Insider Activity

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.36% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.